FibroGen Stock Price, News & Analysis (NASDAQ:FGEN)

$47.30 -0.90 (-1.87 %)
(As of 01/19/2018 06:22 AM ET)
Previous Close$48.20
Today's Range$46.80 - $48.25
52-Week Range$21.05 - $60.15
Volume302,000 shs
Average Volume449,092 shs
Market Capitalization$3.96 billion
P/E Ratio-23.19
Dividend YieldN/A
Beta1.55

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200

Debt

Debt-to-Equity Ratio0.16%
Current Ratio10.83%
Quick Ratio10.83%

Price-To-Earnings

Trailing P/E Ratio-23.1862745098039
Forward P/E Ratio-27.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$179.58 million
Price / Sales21.65
Cash FlowN/A
Price / CashN/A
Book Value$2.77 per share
Price / Book17.08

Profitability

Trailing EPS($2.04)
Net Income$-61,680,000.00
Net Margins-120.00%
Return on Equity-47.36%
Return on Assets-23.51%

Miscellaneous

Employees364
Outstanding Shares82,200,000

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) released its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.13. FibroGen had a negative net margin of 120.00% and a negative return on equity of 47.36%. View FibroGen's Earnings History.

When will FibroGen make its next earnings announcement?

FibroGen is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for FibroGen.

Where is FibroGen's stock going? Where will FibroGen's stock price be in 2018?

7 brokerages have issued twelve-month target prices for FibroGen's shares. Their predictions range from $31.00 to $82.00. On average, they anticipate FibroGen's stock price to reach $65.67 in the next twelve months. View Analyst Ratings for FibroGen.

Who are some of FibroGen's key competitors?

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:

  • Thomas B. Neff, Chairman of the Board, Chief Executive Officer, Founder (Age 62)
  • Pat Cotroneo, Chief Financial Officer, Vice President - Finance (Age 53)
  • Frank H. Valone M.D., Senior Fellow, Clinical Development (Age 66)
  • K. Peony Yu M.D., Chief Medical Officer (Age 54)
  • Gerald Lema, Director
  • Jeffrey L. Edwards, Independent Director (Age 56)
  • Jeffrey William Henderson, Independent Director (Age 52)
  • Thomas F. Kearns Jr., Independent Director (Age 80)
  • Kalevi Kurkijarvi Ph.D., Independent Director (Age 65)

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who owns FibroGen stock?

FibroGen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.44%) and Bank of Montreal Can (0.00%). Company insiders that own FibroGen stock include Frank H Md Valone, Gerald Lema, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Who bought FibroGen stock? Who is buying FibroGen stock?

FibroGen's stock was purchased by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc. and Bank of Montreal Can. View Insider Buying and Selling for FibroGen.

How do I buy FibroGen stock?

Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FibroGen stock can currently be purchased for approximately $47.30.

How big of a company is FibroGen?

FibroGen has a market capitalization of $3.96 billion and generates $179.58 million in revenue each year. The biopharmaceutical company earns $-61,680,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. FibroGen employs 364 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]


MarketBeat Community Rating for FibroGen (FGEN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

FibroGen (NASDAQ:FGEN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.882.882.88
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $65.67$65.67$65.67$42.67
Price Target Upside: 21.49% upside21.49% upside9.26% upside21.04% upside

FibroGen (NASDAQ:FGEN) Consensus Price Target History

Price Target History for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017MizuhoReiterated RatingHold$61.00N/AView Rating Details
9/14/2017Stifel NicolausReiterated RatingBuy$80.00LowView Rating Details
9/12/2017Jefferies GroupReiterated RatingBuy$75.00LowView Rating Details
8/9/2017William BlairReiterated RatingOutperformMediumView Rating Details
8/8/2017Leerink SwannReiterated RatingOutperform -> Outperform$52.00 -> $82.00HighView Rating Details
8/8/2017CitigroupBoost Price TargetTop Pick$48.00 -> $65.00HighView Rating Details
7/21/2017Goldman Sachs GroupDowngradeBuy -> Neutral$31.00MediumView Rating Details
1/18/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingBuy$37.00N/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

FibroGen (NASDAQ:FGEN) Earnings History and Estimates Chart

Earnings by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ FGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.25)N/AView Earnings Details
11/8/2017Q3 2017($0.37)($0.50)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.47)($0.48)$34.80 million$29.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.63)($0.52)$26.02 million$26.89 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.53)($0.54)$19.29 million$31.91 millionViewListenView Earnings Details
11/8/2016Q3($0.63)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
8/8/2016Q2$0.36$0.35$80.58 million$89.28 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$16.89 million$28.28 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)$40.44 million$24.44 millionViewListenView Earnings Details
11/12/2015Q3($0.61)($0.74)$28.74 million$19.54 millionViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.53)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 million$16.11 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

FibroGen (NASDAQ:FGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.75)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.51)($0.48)($0.50)
Q2 20182($0.53)($0.51)($0.52)
Q3 20182($0.53)$1.00$0.24
Q4 20182($0.60)$0.66$0.03
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for FibroGen (NASDAQ:FGEN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

FibroGen (NASDAQ FGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 57.23%
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ FGEN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/28/2018Thomas B NeffCEOSell18,900$48.29$912,681.003,071,705View SEC Filing  
1/5/2018Thomas B NeffCEOSell38,636$47.61$1,839,459.963,029,887View SEC Filing  
12/29/2017Thomas B NeffCEOSell38,636$48.39$1,869,596.04View SEC Filing  
12/21/2017Thomas B NeffCEOSell38,636$44.66$1,725,483.763,022,934View SEC Filing  
12/18/2017Kalevi KurkijarviDirectorSell2,000$42.80$85,600.0022,000View SEC Filing  
12/14/2017K Peony YuInsiderSell2,851$43.70$124,588.70162,086View SEC Filing  
12/14/2017Thomas B NeffCEOSell18,900$42.71$807,219.003,060,887View SEC Filing  
12/12/2017Kalevi KurkijarviDirectorSell12,000$44.45$533,400.0036,000View SEC Filing  
12/11/2017Pat CotroneoVPSell2,851$46.00$131,146.00183,852View SEC Filing  
12/4/2017Gerald LemaDirectorBuy3,500$46.70$163,450.003,500View SEC Filing  
12/1/2017Jorma RouttiDirectorSell12,000$47.25$567,000.00133,840View SEC Filing  
11/17/2017Kalevi KurkijarviDirectorSell2,000$46.65$93,300.0024,000View SEC Filing  
11/16/2017Thomas B NeffCEOSell18,900$46.60$880,740.003,109,555View SEC Filing  
11/15/2017Thomas F Kearns JrDirectorSell18,000$45.22$813,960.00156,564View SEC Filing  
11/6/2017K Peony YuInsiderSell7,500$55.37$415,275.00170,104View SEC Filing  
10/31/2017Thomas B NeffCEOSell38,636$56.13$2,168,638.683,144,573View SEC Filing  
10/17/2017Kalevi KurkijarviDirectorSell2,000$52.24$104,480.0026,000View SEC Filing  
10/17/2017Thomas B NeffCEOSell38,636$55.02$2,125,752.723,176,861View SEC Filing  
10/16/2017Thomas B NeffCEOSell18,900$54.83$1,036,287.003,176,861View SEC Filing  
10/4/2017K Peony YuInsiderSell15,000$60.00$900,000.00View SEC Filing  
10/3/2017Thomas B NeffCEOSell38,636$55.09$2,128,457.24View SEC Filing  
10/2/2017K Peony YuInsiderSell40,000$54.63$2,185,200.00View SEC Filing  
10/2/2017Thomas B NeffCEOSell18,900$54.45$1,029,105.003,217,455View SEC Filing  
9/20/2017Thomas B NeffCEOSell38,636$53.46$2,065,480.563,246,754View SEC Filing  
9/18/2017Kalevi KurkijarviDirectorSell4,000$46.65$186,600.0030,000View SEC Filing  
9/14/2017K Peony YuInsiderSell2,851$51.00$145,401.00185,546View SEC Filing  
9/14/2017Thomas B NeffCEOSell38,636$51.67$1,996,322.123,297,655View SEC Filing  
9/13/2017Rory B RiggsDirectorSell25,000$51.92$1,298,000.00435,200View SEC Filing  
9/13/2017Thomas B NeffCEOSell18,900$51.29$969,381.003,297,655View SEC Filing  
9/11/2017Pat CotroneoVPSell2,851$49.45$140,981.95157,405View SEC Filing  
9/1/2017Jorma RouttiDirectorSell12,000$47.36$568,320.00133,840View SEC Filing  
8/29/2017Thomas B NeffCEOSell38,636$43.73$1,689,552.283,330,780View SEC Filing  
8/28/2017Thomas B NeffCEOSell18,900$43.04$813,456.003,330,780View SEC Filing  
8/21/2017K Peony YuInsiderSell7,500$41.03$307,725.00191,507View SEC Filing  
8/17/2017Kalevi KurkijarviDirectorSell2,000$40.74$81,480.0030,000View SEC Filing  
8/8/2017K Peony YuInsiderSell37,500$50.58$1,896,750.00236,507View SEC Filing  
8/8/2017Pat CotroneoVPSell95,000$50.61$4,807,950.00173,366View SEC Filing  
8/2/2017Pat CotroneoVPSell28,346$33.97$962,913.62170,666View SEC Filing  
8/1/2017K Peony YuInsiderSell10,000$33.48$334,800.00226,507View SEC Filing  
7/25/2017Thomas B NeffCEOSell38,636$35.09$1,355,737.243,330,780View SEC Filing  
7/24/2017Thomas B NeffCEOSell18,900$35.06$662,634.003,330,780View SEC Filing  
7/17/2017Kalevi KurkijarviDirectorSell2,000$33.45$66,900.0032,000View SEC Filing  
7/10/2017K Peony YuInsiderSell5,000$32.98$164,900.00216,507View SEC Filing  
7/7/2017Thomas B NeffCEOSell38,636$33.38$1,289,669.683,330,780View SEC Filing  
7/6/2017Pat CotroneoVPSell4,000$34.00$136,000.00167,366View SEC Filing  
7/6/2017Thomas B NeffCEOSell18,900$33.53$633,717.003,330,780View SEC Filing  
6/22/2017Pat CotroneoVPSell3,000$32.00$96,000.00166,366View SEC Filing  
6/22/2017Thomas B NeffCEOSell38,636$31.52$1,217,806.723,330,780View SEC Filing  
6/19/2017Pat CotroneoVPSell5,500$30.00$165,000.00168,866View SEC Filing  
6/16/2017Thomas B NeffCEOSell38,636$29.40$1,135,898.403,330,780View SEC Filing  
6/15/2017Kalevi KurkijarviDirectorSell2,000$28.50$57,000.0034,000View SEC Filing  
6/14/2017K Peony YuInsiderSell3,721$28.95$107,722.95221,507View SEC Filing  
6/12/2017Pat CotroneoVPSell2,891$28.75$83,116.25163,366View SEC Filing  
6/12/2017Toshinari TamuraDirectorSell30,000$28.89$866,700.0060,000View SEC Filing  
6/6/2017Thomas F Kearns JrDirectorSell18,000$28.71$516,780.00156,564View SEC Filing  
5/31/2017Thomas B NeffCEOSell38,636$26.21$1,012,649.563,345,941View SEC Filing  
5/16/2017Kalevi KurkijarviDirectorSell2,000$27.40$54,800.0036,000View SEC Filing  
5/16/2017Thomas B NeffCEOSell38,636$27.70$1,070,217.203,345,941View SEC Filing  
5/15/2017Thomas B NeffCEOSell18,900$27.75$524,475.003,345,941View SEC Filing  
5/10/2017K Peony YuInsiderSell5,000$26.38$131,900.00227,346View SEC Filing  
4/25/2017K Peony YuInsiderSell5,000$28.00$140,000.00236,046View SEC Filing  
4/25/2017Pat CotroneoVPSell6,500$28.00$182,000.00164,405View SEC Filing  
4/25/2017Thomas B NeffCEOSell38,636$26.92$1,040,081.123,345,941View SEC Filing  
4/24/2017Thomas B NeffCEOSell18,900$26.35$498,015.003,345,941View SEC Filing  
4/17/2017Kalevi KurkijarviDirectorSell2,000$25.25$50,500.0038,000View SEC Filing  
4/13/2017Thomas B NeffCEOSell38,636$24.79$957,786.443,345,941View SEC Filing  
4/4/2017Thomas B NeffCEOSell38,636$23.92$924,173.123,345,941View SEC Filing  
3/21/2017Thomas B NeffCEOSell38,636$24.34$940,400.243,345,941View SEC Filing  
3/20/2017Thomas B NeffCEOSell18,900$24.88$470,232.003,345,941View SEC Filing  
3/15/2017Thomas B NeffCEOSell38,636$25.07$968,604.523,353,983View SEC Filing  
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.0040,000View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.843,274,061View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.003,274,061View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.083,278,868View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.423,288,484View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.0042,000View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.303,298,100View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00138,748View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00202,448View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.523,307,718View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00460,200View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.523,317,334View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20132,248View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.523,317,334View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.403,331,639View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.263,331,639View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00165,564View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.423,341,255View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.483,350,871View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.503,360,487View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.063,360,487View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.333,370,103View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.453,370,103View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.683,379,719View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70206,502View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90134,359View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.023,389,335View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.403,403,639View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.243,413,255View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.003,412,664View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.003,439,764View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04138,114View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.003,466,664View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24210,257View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.003,507,164View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.003,526,053View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20141,868View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.003,552,353View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.003,579,353View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.003,579,353View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.003,606,353View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50115,434View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.003,633,453View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.003,667,175View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00115,133View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.003,596,207View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.003,596,207View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.5096,840View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.003,609,407View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.003,636,407View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76160,564View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.003,663,407View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00162,136View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.003,690,407View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.003,717,407View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28176,595View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.1455,614View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00178,345View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00107,775View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.003,746,689View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00169,936View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.003,746,689View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00169,936View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00183,345View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00187,904View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00187,904View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.0084,044View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.003,773,689View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00177,736View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.0084,044View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00192,904View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00197,904View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.003,800,689View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.003,827,689View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.0084,044View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.003,854,689View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35107,498View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00480,200View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.0012,000View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12202,904View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00107,251View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.003,862,751View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.003,866,782View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.0084,044View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

FibroGen (NASDAQ FGEN) News Headlines

Source:
DateHeadline
Zacks: Brokerages Expect FibroGen Inc (FGEN) to Post -$0.28 Earnings Per ShareZacks: Brokerages Expect FibroGen Inc (FGEN) to Post -$0.28 Earnings Per Share
www.americanbankingnews.com - January 18 at 1:42 AM
FibroGen Inc (FGEN) Given Average Rating of "Buy" by AnalystsFibroGen Inc (FGEN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 12 at 1:50 AM
FibroGen Inc (FGEN) CEO Thomas B. Neff Sells 38,636 SharesFibroGen Inc (FGEN) CEO Thomas B. Neff Sells 38,636 Shares
www.americanbankingnews.com - January 9 at 12:46 AM
Zacks: Brokerages Expect FibroGen Inc (FGEN) Will Post Quarterly Sales of $45.37 MillionZacks: Brokerages Expect FibroGen Inc (FGEN) Will Post Quarterly Sales of $45.37 Million
www.americanbankingnews.com - January 3 at 3:00 PM
FibroGen Inc (FGEN) CEO Sells $912,681.00 in StockFibroGen Inc (FGEN) CEO Sells $912,681.00 in Stock
www.americanbankingnews.com - January 3 at 12:30 AM
Thomas B. Neff Sells 38,636 Shares of FibroGen Inc (FGEN) StockThomas B. Neff Sells 38,636 Shares of FibroGen Inc (FGEN) Stock
www.americanbankingnews.com - January 3 at 12:28 AM
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 1, 2018FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 1, 2018
finance.yahoo.com - January 1 at 9:27 AM
 Brokerages Anticipate FibroGen Inc (FGEN) Will Announce Earnings of -$0.28 Per Share Brokerages Anticipate FibroGen Inc (FGEN) Will Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - January 1 at 7:28 AM
ETFs with exposure to FibroGen, Inc. : December 27, 2017ETFs with exposure to FibroGen, Inc. : December 27, 2017
finance.yahoo.com - December 28 at 2:11 PM
FibroGen (FGEN) Stock Rating Upgraded by BidaskClubFibroGen (FGEN) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 22 at 12:10 AM
Kalevi Kurkijarvi Sells 2,000 Shares of FibroGen Inc (FGEN) StockKalevi Kurkijarvi Sells 2,000 Shares of FibroGen Inc (FGEN) Stock
www.americanbankingnews.com - December 19 at 9:48 PM
Stock Traders Purchase High Volume of Put Options on FibroGen (FGEN)Stock Traders Purchase High Volume of Put Options on FibroGen (FGEN)
www.americanbankingnews.com - December 18 at 3:10 AM
FibroGen Sees Unusually Large Options Volume (FGEN)FibroGen Sees Unusually Large Options Volume (FGEN)
www.americanbankingnews.com - December 18 at 3:10 AM
FibroGen Inc (FGEN) Receives Consensus Rating of "Buy" from BrokeragesFibroGen Inc (FGEN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 18 at 1:54 AM
$45.37 Million in Sales Expected for FibroGen Inc (FGEN) This Quarter$45.37 Million in Sales Expected for FibroGen Inc (FGEN) This Quarter
www.americanbankingnews.com - December 17 at 8:28 AM
K Peony Yu Sells 2,851 Shares of FibroGen Inc (FGEN) StockK Peony Yu Sells 2,851 Shares of FibroGen Inc (FGEN) Stock
www.americanbankingnews.com - December 15 at 9:22 PM
Thomas B. Neff Sells 18,900 Shares of FibroGen Inc (FGEN) StockThomas B. Neff Sells 18,900 Shares of FibroGen Inc (FGEN) Stock
www.americanbankingnews.com - December 15 at 8:52 PM
ETFs with exposure to FibroGen, Inc. : December 15, 2017ETFs with exposure to FibroGen, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 5:56 PM
-$0.28 Earnings Per Share Expected for FibroGen Inc (FGEN) This Quarter-$0.28 Earnings Per Share Expected for FibroGen Inc (FGEN) This Quarter
www.americanbankingnews.com - December 15 at 11:06 AM
FibroGen Inc (FGEN) VP Pat Cotroneo Sells 2,851 SharesFibroGen Inc (FGEN) VP Pat Cotroneo Sells 2,851 Shares
www.americanbankingnews.com - December 13 at 9:50 PM
FibroGen Inc (FGEN) Director Sells $533,400.00 in StockFibroGen Inc (FGEN) Director Sells $533,400.00 in Stock
www.americanbankingnews.com - December 13 at 9:28 PM
Comparing FibroGen (FGEN) and Celyad (CYAD)Comparing FibroGen (FGEN) and Celyad (CYAD)
www.americanbankingnews.com - December 10 at 5:20 PM
FibroGen (FGEN) Downgraded by BidaskClub to SellFibroGen (FGEN) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - December 9 at 6:32 PM
Analysts Predict 22% Upside For PBE - NasdaqAnalysts Predict 22% Upside For PBE - Nasdaq
www.nasdaq.com - December 7 at 5:46 PM
Insider Buying: FibroGen, Inc (FGEN) Director Acquires 3,500 Shares of StockInsider Buying: FibroGen, Inc (FGEN) Director Acquires 3,500 Shares of Stock
www.americanbankingnews.com - December 5 at 9:30 PM
FibroGen is Now Oversold (FGEN)FibroGen is Now Oversold (FGEN)
www.nasdaq.com - December 5 at 10:11 AM
Jorma Routti Sells 12,000 Shares of FibroGen, Inc (FGEN) StockJorma Routti Sells 12,000 Shares of FibroGen, Inc (FGEN) Stock
www.americanbankingnews.com - December 4 at 11:22 PM
FibroGen (FGEN) Cut to "Sell" at ValuEngineFibroGen (FGEN) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 2:20 PM
Zacks: Brokerages Anticipate FibroGen, Inc (FGEN) Will Post Quarterly Sales of $45.37 MillionZacks: Brokerages Anticipate FibroGen, Inc (FGEN) Will Post Quarterly Sales of $45.37 Million
www.americanbankingnews.com - November 29 at 10:32 AM
Zacks: Brokerages Anticipate FibroGen, Inc (FGEN) to Announce -$0.28 EPSZacks: Brokerages Anticipate FibroGen, Inc (FGEN) to Announce -$0.28 EPS
www.americanbankingnews.com - November 27 at 5:26 AM
FibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from AnalystsFibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 23 at 1:52 AM
FibroGen, Inc (FGEN) Director Sells $93,300.00 in StockFibroGen, Inc (FGEN) Director Sells $93,300.00 in Stock
www.americanbankingnews.com - November 20 at 10:54 PM
ETFs with exposure to FibroGen, Inc. : November 20, 2017ETFs with exposure to FibroGen, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 7:23 PM
FibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 18,900 SharesFibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 18,900 Shares
www.americanbankingnews.com - November 17 at 8:10 PM
Thomas F. Kearns, Jr. Sells 18,000 Shares of FibroGen, Inc (FGEN) StockThomas F. Kearns, Jr. Sells 18,000 Shares of FibroGen, Inc (FGEN) Stock
www.americanbankingnews.com - November 17 at 8:10 PM
FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 13 at 10:07 AM
FY2017 EPS Estimates for FibroGen, Inc (FGEN) Increased by AnalystFY2017 EPS Estimates for FibroGen, Inc (FGEN) Increased by Analyst
www.americanbankingnews.com - November 13 at 3:36 AM
William Blair Research Analysts Increase Earnings Estimates for FibroGen, Inc (FGEN)William Blair Research Analysts Increase Earnings Estimates for FibroGen, Inc (FGEN)
www.americanbankingnews.com - November 13 at 3:36 AM
FibroGen, Inc (FGEN) to Post FY2017 Earnings of ($1.75) Per Share, Jefferies Group ForecastsFibroGen, Inc (FGEN) to Post FY2017 Earnings of ($1.75) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 13 at 3:36 AM
Edited Transcript of FGEN earnings conference call or presentation 8-Nov-17 10:00pm GMTEdited Transcript of FGEN earnings conference call or presentation 8-Nov-17 10:00pm GMT
finance.yahoo.com - November 10 at 4:25 PM
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017
finance.yahoo.com - November 10 at 4:25 PM
Q3 2018 EPS Estimates for FibroGen, Inc Raised by William Blair (FGEN)Q3 2018 EPS Estimates for FibroGen, Inc Raised by William Blair (FGEN)
www.americanbankingnews.com - November 10 at 4:20 PM
OTIC Data Music To Ears, Apellis IPO Opens Today, CAPR High On HOPE - NasdaqOTIC Data Music To Ears, Apellis IPO Opens Today, CAPR High On HOPE - Nasdaq
www.nasdaq.com - November 9 at 3:24 AM
Commit To Buy FibroGen At $40, Earn 13.5% Annualized Using Options - NasdaqCommit To Buy FibroGen At $40, Earn 13.5% Annualized Using Options - Nasdaq
www.nasdaq.com - November 9 at 3:24 AM
FibroGen Reports Third Quarter 2017 Financial Results Nasdaq:FGEN - GlobeNewswire (press release)FibroGen Reports Third Quarter 2017 Financial Results Nasdaq:FGEN - GlobeNewswire (press release)
globenewswire.com - November 9 at 3:23 AM
Is It Too Late To Buy FibroGen Inc (FGEN)?Is It Too Late To Buy FibroGen Inc (FGEN)?
finance.yahoo.com - November 9 at 3:23 AM
FibroGen, Inc. to Host Earnings CallFibroGen, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 3:23 AM
FibroGen Reports Third Quarter 2017 Financial ResultsFibroGen Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 3:23 AM
FibroGen reports 3Q lossFibroGen reports 3Q loss
finance.yahoo.com - November 9 at 3:23 AM
ETFs with exposure to FibroGen, Inc. : November 8, 2017ETFs with exposure to FibroGen, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 3:23 AM

SEC Filings

FibroGen (NASDAQ:FGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

FibroGen (NASDAQ:FGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

FibroGen (NASDAQ FGEN) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.